Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,152 | 411 | 2,711 |
| Samples | 1,023 | 179 | 833 |
| Peptides | 736 | 121 | 653 |
Function
CDH12 · Cadherin 12
This gene encodes a type II classical cadherin of the cadherin superfamily. Alternative splicing of this gene results in multiple transcript variants. At least one of these variants encodes a preproprotein that is proteolytically processed to generate the mature cadherin protein. These integral membrane proteins mediate calcium-dependent cell-cell adhesion and are composed of a large N-terminal extracellular domain, a single membrane-spanning domain, and a small, highly conserved C-terminal cytoplasmic domain. Type II (atypical) cadherins are defined based on their lack of a histidine-alanine-valine (HAV) cell adhesion recognition sequence specific to type I cadherins. This particular cadherin appears to be expressed specifically in the brain and its temporal pattern of expression would be consistent with a role during a critical period of neuronal development, perhaps specifically during synaptogenesis. [provided by RefSeq, Nov 2015].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 712 amino-acid changes on canonical ENST00000382254 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDH12 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDH12 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 41/304 13% | 99/1390 7% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 58/810 7% |
| Endometrial Carcinoma | 8/42 19% | 35/612 6% |
| Melanoma | 15/210 7% | 103/1899 5% |
| Gastric Carcinoma | 4/74 5% | 69/1809 4% |
| Small Cell Lung Carcinoma | 1/9 11% | 28/752 4% |
| Colorectal Carcinoma | 23/143 16% | 105/3239 3% |
| Neuroendocrine Tumour | 6/154 4% | 17/577 3% |
| Other Solid Cancers | 4/94 4% | 42/1515 3% |
| Esophageal Carcinoma | 1/23 4% | 17/769 2% |
| Cervical Carcinoma | 0/35 0% | 10/422 2% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Bladder Carcinoma | 1/58 2% | 19/956 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Esophageal Squamous Cell Carcinoma | 8/51 16% | 38/2550 1% |
| Other Sarcomas | 1/69 1% | 10/699 1% |
| Head and Neck Carcinoma | 1/85 1% | 22/1574 1% |
| Mesothelioma | 2/62 3% | 1/165 1% |
| Prostate Carcinoma | 0/13 0% | 27/2105 1% |
| Plasma Cell Myeloma | 1/44 2% | 3/305 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Hepatocellular Carcinoma | 3/46 7% | 20/2210 1% |
| Ovarian Carcinoma | 3/109 3% | 8/998 1% |
| Breast Carcinoma | 4/144 3% | 28/3264 1% |
Mutation Distribution
Where CDH12 is mutated · all tissues, split by cell line vs tissue
How many mutations in CDH12 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 43 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,152 mutations in CDH12
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|